Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?

Nature Clinical Practice Oncology volume 4, pages 686–687 (2007)Cite this article

boxed-textMoore MJ et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960–1966

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cunningham D et al. (2005) Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer [abstract #PS11]. Eur J Cancer Suppl 3: a12

    Google Scholar 

  2. Herrmann R et al. (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25: 2212–2217

    Article  CAS  Google Scholar 

  3. Oettle H et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 297: 267–277

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. H Oettle is an Associate Professor and A Hilbig is a Clinical Research Fellow in the Department of Medical Oncology and Hematology at the Charité School of Medicine, Berlin, Germany.,

    Helmut Oettle & Andreas Hilbig

Authors
  1. Helmut Oettle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Hilbig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helmut Oettle.

Ethics declarations

Competing interests

H Oettle has received speakers' bureau honoraria from Roche and Lilly and grant/research support from Roche, Lilly and Sanofi Aventis. A Hilbig declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oettle, H., Hilbig, A. Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?. Nat Rev Clin Oncol 4, 686–687 (2007). https://doi.org/10.1038/ncponc0960

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0960

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing